Experimental drug combo targets Hard-to-Treat HER2 cancers
NCT ID NCT07137416
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgically removed. Pidnarulex is an enzyme blocker that kills cancer cells, while trastuzumab deruxtecan is a targeted therapy that delivers chemotherapy directly to HER2-positive cells. The goal is to find a tolerable dose and see early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Washington University School of Medicine
SUSPENDEDSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pidnarulex and trastuzumab deruxtecan
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced HER2-positive or HER2-low breast cancer and other solid tumors.
What could go wrong
This is a very early Phase 1 trial with only 36 participants. The main goal is safety and dosing, not proof of effectiveness. Side effects from the drug combination could be significant, and many early-stage cancer trials do not lead to approved treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.